Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices.
Our products and solutions
We offer a wide range of injection systems, digital health solutions, and future-focused innovations for pharma clients.
As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions.
Our platform ecosystem combines industrialized drug delivery technology with a set of built-in and optional services that support every stage of development.
Ypsomed enhances self-injection device platforms with integrated human factors services
Streamline clinical development with Ypsomed
Clear to Clinic
Clinic-ready devices to accelerate trial readiness and reduce study risk Speed defines success in clinical development. Participant recruitment constraints, lengthy dose-finding protocols, and device bridging timelines create critical delays. Clear to Clinic enables the use of clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and derisk your program.
Burgdorf – CEO Simon Michel provides an update on Ypsomed's (SIX: YPSN) first quarter of fiscal year 2026/27. Thanks to new customer projects spanning many therapeutic areas, international recognition for its innovation, and the planned expansion of …
From 2 to 6 September, Ypsomed showcased the wide range of apprenticeship opportunities available at our company at the BAM Career and Training Fair in Bern. Numerous students visited our booth, spoke with our apprentices and vocational trainers, and …
DPHARM unites clinical operations leaders to explore approaches to improving clinical trial execution. Attend Tobias Theiler's presentation on how connected autoinjector technology can automate drug accountability in decentralized clinical trials.
PDA Japan Combination Products Seminar 2026 brings together experts in injectable combination products to discuss the latest advances in parenteral systems, prefilled syringes, and injection devices. Meet Ypsomed in Tokyo.
The pharmaceutical industry heads to China this September for CPHI & PMEC Shenzhen, with biotech, R&D, and manufacturing among the key areas of focus. Located at the heart of the Greater Bay Area, the event provides a gateway to the wider Asian market.
We pursue a long-term corporate strategy based on four pillars. These four pillars stand for areas of action in which we fulfill our responsibility to society as a sustainably oriented company.
We are committed to acting responsibly towards our employees, our partners and society. We are also committed to the circular economy and reducing our carbon footprint.